Myung-Ju Ahn

50PUBLICATIONS
340CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Deep learning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Jun 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Jun 01, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

|Apr 27, 2026
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.

|Apr 22, 2026
Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.

Pageof 9

Frequent Collaborators

11 joint publications

Byoung Chul Cho

8 joint publications

Hyun-Ae Jung

6 joint publications

James Chih-Hsin Yang

6 joint publications

Enriqueta Felip